The NOAC benefit expanssion has heated competition of the anti-coagulant market
By the benefit expansion of the new oral anti-coagulant(NOAC), competition in the NOAC market is expected to be serious.
As the Ministry of Health and Welfare revised and issued the benefit expansion to the primary drug for the high-risk group of non-valvular atrial fibrillation patients, which ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
